Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

129 trials

NCT06043011
Recruiting
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Not applicable · Germany · 1 site
Registry update: 13 Jul 2026
NCT05365659
Recruiting
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Phase 1 · Australia, Canada, Spain, Italy, United States · 13 sites
Registry update: 3 Nov 2026
NCT05861050
Recruiting
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
Phase 1/2 · United States · 3 sites
Registry update: 26 Oct 2026
NCT05602363
Recruiting
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Phase 1 · United States · 13 sites
Registry update: 10 Dec 2025
NCT05432635
Recruiting
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
Phase 1 · United States · 1 site
Registry update: 23 Feb 2026
NCT05659732
Recruiting
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer
Phase 1 · Australia, Taiwan · 5 sites
Registry update: 31 Jul 2025
NCT05780034
Recruiting
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Phase 1 · United States · 9 sites
Registry update: 2 Oct 2025
2022-501808-96-00
Recruiting
Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with Mantle Cell Lymphoma.
Phase 2 · Germany, Italy · 41 sites
Registry update: 3 Nov 2026
NCT05544019
Recruiting
Study of SGR-1505 in Mature B-Cell Neoplasms
Phase 1 · Spain, France, Italy, Moldova, Poland, Romania, Ukraine, United States · 37 sites
Registry update: 13 Feb 2026
NCT05643742
Recruiting
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Phase 1/2 · Australia, United States · 7 sites
Registry update: 14 Nov 2025
NCT05724121
Recruiting
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Not applicable · United States · 1 site
Registry update: 29 Oct 2026
NCT05529069
Recruiting
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Phase 2 · United States · 1 site
Registry update: 5 May 2026
NCT05643235
Recruiting
Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors
Not applicable · United States · 1 site
Registry update: 18 Sept 2025
NCT05245656
Recruiting
A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma
Phase 2 · South Korea · 1 site
Registry update: 23 Apr 2026
NCT05506410
Recruiting
A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
Not applicable · China · 1 site
Registry update: 18 Aug 2022
NCT05992597
Recruiting
ZR2 Sequential Immunochemotherapy for Newly Treated MCL
Phase 2 · China · 1 site
Registry update: 21 Sept 2023
NCT05370430
Recruiting
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
Phase 1 · United States · 5 sites
Registry update: 10 Nov 2026
NCT05255354
Recruiting
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
Not applicable · United States · 1 site
Registry update: 22 Aug 2024
NCT05294731
Recruiting
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Phase 1/2 · China · 29 sites
Registry update: 21 Oct 2026
NCT05281809
Recruiting
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Phase 2 · United States · 1 site
Registry update: 13 Jan 2025

Ordered by registry start date. Freshness and sponsorship never change the order.